A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression

International Clinical Psychopharmacology

Volumn 22, Issue 6, 2007, Pages 371-375

  Mazeh, Doron ^a,b   Shahal, Baruch ^a,b   Aviv, Alex ^a,b   Zemishlani, Hanna ^a,b   Barak, Yoram ^a,b  

^a ABARBANEL MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Elderly; Paroxetine; Resistant depression; Venlafaxine

Indexed keywords

PAROXETINE; VENLAFAXINE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GERIATRIC DEPRESSION SCALE; GERIATRIC PATIENT; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MALE; MENTAL PATIENT; NAUSEA; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REMISSION; SAMPLE SIZE; SEDATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMANS; MALE; NAUSEA; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; XEROSTOMIA;

EID: 34948821737     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32817396ae     Document Type: Article

References (28)

1. Amore M, Ricci M, Zanardi R, Perez Jferrari G (1997). Long-term treatment of geropsychiatric depressed patients with venlafaxine. J Affect Disord 46:293-296.
2. Ballus C, Quiros G, de Flores T, de la Torre J, Palao D, Rojo L, et al. (2000). The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin psychopharmacol 15:43-48.
3. Blazer DG, Cassel CK (1994). Depression in the elderly. Hosp Pract 15:37-44.
4. Brink TL, Yesavage JA, Lum O, Heersema P, Adey MB, Rose TL (1982). Screening tests for geriatric depression. Clin Gerontologist 1:37-44.
5. Dierick M (1996). An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 8:169-178.
6. Dierick M, Ravizza L, Realini R, Martin A (1996). A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 20:57-71.
7. Ekselius L, von Knorring L, Eberhard G (1997). A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 12:323-331.
8. Fava M, Davidson KG (1996). Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19:179-200.
9. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, et al. (2006). A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163:1161-1172.
10. Fleck MP, Horwath E (2005). Pharmacologic management of difficult-to-treat depression in clinical practice. Psychiatr Serv 56:1005-1011.
11. Flynn MS, Flynn P (1991). How to identify and treat depression in the elderly. Geriatrics 27-41.
12. Guy W (1976). ECDEU assessment manual for psychopharmacology, revised. US dept health, education, and welfare publication (ADM). Rockville, Maryland: National Institute of Mental Health. pp. 76-338.
13. Hamilton M (1967). Development of rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
14. Holliday SM, Benfield P (1995). Venlafaxive-a review of its pharmacology and therapeutic potential in depression. Drugs 49:280-294.
15. Khan A, Rudolph R, Baumel B, Ferguson J, Ryan P, Shrivastava R (1995). Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharmacol Bull 31:753-758.
16. Keller MB (2005). Issues in treatment-resistant depression. J Clin Psychiatry 66 (Suppl 8):5-12.
17. McGuire MH, Rabins PV (1994). Mood disorders. In: Coffey CE, Cummings JL, Lovell MR, Pearlson GD, editors. The American psychiatric press textbook of psychopharmacology. Washington, DC: American Psychiatric Press. pp. 244-260.
18. Nemeroff CB (1993). Paroxetine: an overview of the efficacy and safety of a new selective seratonin reuptake inhibitor in the treatment of depression. J Clin Psychopharm 13 (Suppl 2):10S-17S.
19. NIH (1992). Consensus development panel on depression in late life. Depression and treatment of depression in late life. JAMA 268:1018-1024.
20. Poirier MF, Boyer P (1999a). Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry 175:12-16.
21. Quitkin FM, McGrath PJ, Stewart JW, Deliyannides D, Taylor BP, Davies CA, et al. (2005). Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. J Clin Psychiatry 66:670-676.
22. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. (2006). Bupropion-SR, sertaline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231-1242.
23. Salzman C, Satlin A, Burrows AB (1995). Geriatric psychopharmacology. In: Schttberg AF, Nemeroff CB, editors. The American Psychiatric Press textbook of psychopharmacology. Washington, DC: American Psychiatric Press. pp. 803-821.
24. Solomon PR, Pendlebury WW (1998). Recognition of Alzheimer's disease: the 7 min screen. Fam Med 30:265-271.
25. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, et al. (1999). Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 9:83-91.
26. Thase ME (2003). Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry 13 (64 Suppl):18-25.
27. Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241.
28. Zimmerman M, Chelminski I, Posternak M (2004). A review of studies of the Hamilton depression rating scale in healthy controls: implications for the definition of remission in treatment studies of depression. J Nerv Ment Dis 192:595-601.